Impact of SARS-CoV-2 antibodies at delivery in women, partners and newborns

Egerup, Pia; Olsen, Line; Christiansen, Ann-Marie Hellerung; Westergaard, David; Severinsen, Elin Rosenbek; Hviid, Kathrine Vauvert Römmelmayer; Kolte, Astrid Marie; Boje, Amalie Dyhrberg; Bertelsen, Marie-Louise Mathilde Friis; Prætorius, Lisbeth; Zedeler, Anne; Nielsen, Josefine Reinhardt; Bang, Didi; Berntsen, Sine; Ethelberg-Findsen, Jeppe; Storm, Ditte Marie; Bello-Rodríguez, Judith; Ingham, Andreas; Ollé-López, Joaquim; Hoffmann, Eva R.; Wilken‐Jensen, Charlotte; Krebs, Lone; Jørgensen, Finn Stener; Westh, Henrik; Jørgensen, Henrik L.; Freiesleben, Nina la Cour; Nielsen, Henriette Svarre

doi:10.1101/2020.09.14.20191106

Cited by 2 publications

(3 citation statements)

References 16 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four studies examined the seroprevalence of SARS-CoV-2 in pregnant women [ 37 , 50 , 83 , 97 ]. Two of these studies conducted in Italy between April–June 2020 reported a prevalence of SARS-CoV-2 antibodies of 10.1% and 14.3% in pregnant women in their first trimester screening or at delivery [ 83 , 97 ].…”

Section: Resultsmentioning

confidence: 99%

“…Egerup et al investigate the seroprevalence among pregnant women, their partners and newborn babies [ 37 ]. They report a seroprevalence of 2.85% among parturient women, 3.8% among partners and 1.4% among newborn babies [ 37 ]. They report no association between COVID-19 and obstetric or neonatal complications [ 37 ].…”

Section: Resultsmentioning

confidence: 99%

“…They report a seroprevalence of 2.85% among parturient women, 3.8% among partners and 1.4% among newborn babies [ 37 ]. They report no association between COVID-19 and obstetric or neonatal complications [ 37 ].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

The seroprevalence of SARS-CoV-2 during the first wave in Europe 2020: A systematic review

et al. 2021

View full text Add to dashboard Cite

Background A year following the onset of the COVID-19 pandemic, new infections and deaths continue to increase in Europe. Serological studies, through providing evidence of past infection, can aid understanding of the population dynamics of SARS-CoV-2 infection. Objectives This systematic review of SARS-CoV-2 seroprevalence studies in Europe was undertaken to inform public health strategies including vaccination, that aim to accelerate population immunity. Methods We searched the databases Web of Science, MEDLINE, EMBASE, SCOPUS, Cochrane Database of Systematic Reviews and grey literature sources for studies reporting seroprevalence of SARS-CoV-2 antibodies in Europe published between 01/12/2019–30/09/20. We provide a narrative synthesis of included studies. Studies were categorized into subgroups including healthcare workers (HCWs), community, outbreaks, pregnancy and children/school. Due to heterogeneity in other subgroups, we only performed a random effects meta-analysis of the seroprevalence amongst HCWs stratified by their country. Results 115 studies were included spanning 17 European countries, that estimated the seroprevalence of SARS-CoV-2 from samples obtained between November 2019 –August 2020. A total of 54/115 studies included HCWs with a reported seroprevalence among HCWs ranging from 0.7% to 45.3%, which did not differ significantly by country. In community studies significant heterogeneity was reported in the seroprevalence between different age groups and the majority of studies reported there was no significant difference by gender. Conclusion This review demonstrates a wide heterogeneity in reported seroprevalence of SARS-CoV-2 antibodies between populations. Continued evaluation of seroprevalence is required to understand the impact of public health measures and inform interventions including vaccination programmes.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The seroprevalence of SARS-CoV-2 during the first wave in Europe 2020: A systematic review

et al. 2021

View full text Add to dashboard Cite

show abstract

SARS-CoV-2 in pregnancy and possible transfer of immunity: assessment of peripartal maternal and neonatal antibody levels and a longitudinal follow-up

Rathberger

Häusler

Wellmann

et al. 2021

Journal of Perinatal Medicine

View full text Add to dashboard Cite

Objectives In the current Severe Acute Respiratory Distress Coronavirus 2 (SARS-CoV-2) pandemic there is still great uncertainty about the effects of an infection in pregnancy especially regarding a possible fetal transmission of antibodies to SARS-CoV-2 and the longevity of this immunity. Methods Sixteen women who were infected with SARS-CoV-2 during pregnancy and their offspring were included. The antibody response to SARS-CoV-2 was measured in mother and umbilical cord blood peripartum and in a follow-up examination 6–11 weeks after birth. Medical history, symptoms regarding SARS-CoV-2, obstetric and neonatal information were queried following recommendations by the WHO. Results A total of 73% of the women and one third of the infants developed antibodies to SARS-CoV-2 spike (S) protein receptor binding domain (RBD), with a long interval between infection and birth proving favorable for a transplacentar transfer of antibodies to the neonates. All infants showed declining or vanishing antibody-titers in the follow-up examination, while the titers of their mothers were stable or even increased. Conclusions Our results demonstrate that transplacental transfer of SARS-CoV-2-specific antibodies is possible, but also indicate that the immunity that may be gained as a result might decrease in newborns postpartum. This provides important evidence that could be useful for further studies covering vaccination during pregnancy.

show abstract

Impact of SARS-CoV-2 antibodies at delivery in women, partners and newborns

Cited by 2 publications

References 16 publications

The seroprevalence of SARS-CoV-2 during the first wave in Europe 2020: A systematic review

The seroprevalence of SARS-CoV-2 during the first wave in Europe 2020: A systematic review

SARS-CoV-2 in pregnancy and possible transfer of immunity: assessment of peripartal maternal and neonatal antibody levels and a longitudinal follow-up

Contact Info

Product

Resources

About